Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exisulind in Prostate Cancer Patients on Intermittent Androgen Suppression
NCT00283803Phase 2Completed
- Sponsor
- University of Washington
- Start
- Mar 2002
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exisulind in prostate cancer (PCa), sponsored by University of Washington. Primary endpoints: Duration of the First 'Off-treatment' Cycle in Patients Who Have Completed One Cycle of Intermittent Androgen Suppression With the Addition of Exisulind up to 10 years, Time to Hormone-refractory Diseases in Patients Treated With Intermittent Androgen Suppression and Exisulind up to 10 years and 1 more. Started Mar 2002; status: completed.
02
Drugs
exisulind
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00283803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00283803.